Grünenthal Press Releases 2006

Aachen, Germany, 15 December, 2006. Switching between different opioids is frequently used in patients with chronic pain either to improve pain relief, or as a way of reducing adverse effects. Determining the correct dosage of each opioid relies on the use of conversion tables which reflect the potency of each drug. As a result of recent experimental and clinical studies it has been realised that previous estimates of the potency of Transtec® may be too low.

Aachen, Germany, 5 December 2006. The need for greater awareness and better management of chronic pain in the 65+ age group is now being recognized by international pain associations. IASP promotes the Global Day and Global Year Against Pain in Older Persons to raise awareness of pain worldwide. Transtec® provides effective management of chronic pain and offers advantages in terms of safety, tolerability and ease of handling particularly important in this age group.

Aachen, Germany, 22 November, 2006. Winners of the 2006 EFIC Grünenthal Grant (E-G-G) today presented their proposals for innovative and exploratory clinical and human experimental research projects in the field of pain to an audience of international opinion leaders and experts in pain therapy.

Istanbul, 18 September, 2006. Winners of the 2005 and 2004 EFIC Grünenthal Grant (E-G-G) presented results of the funded projects with innovative clinical research toward a better understanding of pain and novel approaches for treating patients suffering from acute and chronic pain. The data were announced at the close of the Fifth Triennial Congress of the EFIC, a conference bringing together over 5000 researchers from across Europe.

Aachen, Germany, 16 September 2006. As part of the 102nd Annual Meeting of the German Society of Paediatric and Adolescent Medicine in Mainz Grünenthal GmbH introduced a unique system for administering antibiotics: ClaroSip®, clarithromycin in a drinking straw. An innovation, which ensures high compliance particularly in children.

Aachen, Germany, 15 September 2006. At the 5th Congress of the European Federation of IASP® Chapters (EFIC) in Istanbul, Turkey, Grünenthal GmbH presented positive results on preclinical and early clinical studies of Tapentadol (CG5503 / R331333).

Aachen, Germany, 6 June 2006. At the American Pain Society Meeting in San Antonio, Texas, Grünenthal GmbH presented positive results on preclinical and early clinical studies of tapentadol (CG5503 / R331333).

Aachen, Germany, 1 June 2006. At the 9th Congress of the European Society of Contraception, the international, research-based, pharmaceutical company Grünenthal presented the results of their phase III Balance Study, which evaluated the efficacy and safety of Belara® during administration for six medication cycles in patients with papulo-pustular acne.

Cambridge, United Kingdom/Aachen, Germany, 26 April 2006. Mundipharma International Limited and Grünenthal GmbH announce the signing of an agreement that will help to bring NorspanTM, the world's first 7-day transdermal patch for the treatment of moderate to severe opioid-sensitive chronic pain, to pain patients across Europe.

Aachen, Germany/Florence, Italy, 3 March 2006. At the 12th World Congress of Gynaecological Endocrinology the pharma­ceutical company Grünenthal introduces Belara® in Europe